JP7357634B2 - Urat-1阻害剤の新規塩型 - Google Patents

Urat-1阻害剤の新規塩型 Download PDF

Info

Publication number
JP7357634B2
JP7357634B2 JP2020551976A JP2020551976A JP7357634B2 JP 7357634 B2 JP7357634 B2 JP 7357634B2 JP 2020551976 A JP2020551976 A JP 2020551976A JP 2020551976 A JP2020551976 A JP 2020551976A JP 7357634 B2 JP7357634 B2 JP 7357634B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
substantially pure
crystalline form
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519313A (ja
JP2021519313A5 (cg-RX-API-DMAC7.html
Inventor
シン タイ
ユエハン チアン
Original Assignee
インベンティスバイオ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンティスバイオ カンパニー リミテッド filed Critical インベンティスバイオ カンパニー リミテッド
Publication of JP2021519313A publication Critical patent/JP2021519313A/ja
Publication of JP2021519313A5 publication Critical patent/JP2021519313A5/ja
Application granted granted Critical
Publication of JP7357634B2 publication Critical patent/JP7357634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
JP2020551976A 2018-03-28 2019-03-26 Urat-1阻害剤の新規塩型 Active JP7357634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/080889 2018-03-28
PCT/CN2018/080889 WO2019183835A1 (en) 2018-03-28 2018-03-28 Novel salt forms of urat-1 inhibitors
PCT/CN2019/079619 WO2019184897A1 (en) 2018-03-28 2019-03-26 Novel salt forms of urat-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2021519313A JP2021519313A (ja) 2021-08-10
JP2021519313A5 JP2021519313A5 (cg-RX-API-DMAC7.html) 2022-03-22
JP7357634B2 true JP7357634B2 (ja) 2023-10-06

Family

ID=68059457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551976A Active JP7357634B2 (ja) 2018-03-28 2019-03-26 Urat-1阻害剤の新規塩型

Country Status (10)

Country Link
US (2) US11339127B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774733B1 (cg-RX-API-DMAC7.html)
JP (1) JP7357634B2 (cg-RX-API-DMAC7.html)
KR (1) KR102907394B1 (cg-RX-API-DMAC7.html)
CN (1) CN111902398B (cg-RX-API-DMAC7.html)
AU (1) AU2019241202B2 (cg-RX-API-DMAC7.html)
CA (1) CA3094292A1 (cg-RX-API-DMAC7.html)
IL (1) IL277578A (cg-RX-API-DMAC7.html)
TW (1) TWI818001B (cg-RX-API-DMAC7.html)
WO (2) WO2019183835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234060B (zh) * 2021-04-30 2022-11-08 山东大学 一种稠杂环吡啶巯乙酸类衍生物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528655A (ja) 2010-06-16 2013-07-11 アルデア バイオサイエンシーズ インク. チオ酢酸化合物、組成物、および、その使用方法
JP2013530186A (ja) 2010-06-16 2013-07-25 アルデア バイオサイエンシーズ インク. フェニルチオ酢酸化合物、組成物、および、その使用方法
JP2017524704A (ja) 2014-08-13 2017-08-31 シャンハイ シェイルテック テクノロジー カンパニー リミテッド カルボン酸化合物、その製造方法および使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8549908B2 (en) * 2010-06-17 2013-10-08 Los Robles Advertising, Inc. Thermal anemometer flow meter for the measurement of wet gas flow

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528655A (ja) 2010-06-16 2013-07-11 アルデア バイオサイエンシーズ インク. チオ酢酸化合物、組成物、および、その使用方法
JP2013530186A (ja) 2010-06-16 2013-07-25 アルデア バイオサイエンシーズ インク. フェニルチオ酢酸化合物、組成物、および、その使用方法
JP2017524704A (ja) 2014-08-13 2017-08-31 シャンハイ シェイルテック テクノロジー カンパニー リミテッド カルボン酸化合物、その製造方法および使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmaceutical Sciences,1977年,66(1),P.1-19
薬剤学,2006年,66(6),P.435-439

Also Published As

Publication number Publication date
US20220371996A1 (en) 2022-11-24
KR20200138260A (ko) 2020-12-09
US11685720B2 (en) 2023-06-27
EP3774733A4 (en) 2021-12-01
CN111902398B (zh) 2024-01-26
WO2019184897A1 (en) 2019-10-03
JP2021519313A (ja) 2021-08-10
EP3774733C0 (en) 2025-09-24
US20210032204A1 (en) 2021-02-04
WO2019183835A1 (en) 2019-10-03
EP3774733B1 (en) 2025-09-24
US11339127B2 (en) 2022-05-24
EP3774733A1 (en) 2021-02-17
AU2019241202A1 (en) 2020-10-01
KR102907394B1 (ko) 2025-12-31
CN111902398A (zh) 2020-11-06
CA3094292A1 (en) 2019-10-03
AU2019241202B2 (en) 2024-06-13
TW202003467A (zh) 2020-01-16
IL277578A (en) 2020-11-30
TWI818001B (zh) 2023-10-11

Similar Documents

Publication Publication Date Title
US12018025B2 (en) Integrin inhibitor and uses thereof
US9221815B2 (en) Solid state form of vemurafenib choline salt
JP2010514807A (ja) 溶媒和物化されたイラプラゾールの結晶形
US20220002297A1 (en) Polymorphs of x842
US12030895B2 (en) Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound
US11230533B2 (en) Crystalline salts and polymorphs of a P2X3 antagonist
JP2026512051A (ja) ベンズイミダゾール誘導体の塩
US20250326743A1 (en) Crystal forms of triazine dione derivative and preparation method therefor
TWI540131B (zh) 阿瑞吡坦(aprepitant)l-脯胺酸組成物及共晶體
US11685720B2 (en) Salt forms of URAT-1 inhibitors
RS60749B1 (sr) Natrijumova so inhibitora transportera mokraćne kiseline i njen kristalni oblik
US10633376B2 (en) Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereof
US20250197393A1 (en) Integrin inhibitor and uses thereof
EP3412661A1 (en) Cocrystals of vortioxetine hydrobromide and resorcinol
US20250368639A1 (en) Solid forms of a compound for treating or preventing hyperuricemia or gout
US20060194833A1 (en) Crystalline 1H-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
JP2024545530A (ja) 縮合環誘導体の結晶形、その製造方法、及びその使用
CN115003653A (zh) 艾拉菲诺的多晶型物
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230926

R150 Certificate of patent or registration of utility model

Ref document number: 7357634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250